Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02017704 · ClinicalTrials.gov registry record · Phase 2
Chemoradiation or Brachytherapy for Rectal Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02017704: Completed Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT02017704 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02017704, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).
Primary Outcome
Pathologic complete response rate is reported as the number of patients who achieve pathologic complete response after the treatment for each arm. As per the NCCN guidelines, pathologic response is graded by the system recommended by the AJCC Cancer Staging Manual and CAP guidelines: * Complete response - no remaining viable cancer cells * Moderate response - only small clusters/single cancer cells remain * Minimal response - residual cancer remaining, but with predominant fibrosis * Poor resp
Interventions
- PROCEDURE Surgery
- RADIATION IMRT (intensity modulated radiation therapy)
- DRUG FOLFOX6
- RADIATION Endo-HDR (if randomized to this arm)
- DRUG capecitabine and IMRT (if randomized to this arm)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-06-12 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 2 |
What the finished NCT02017704 record still lists
NCT02017704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 5 interventions - of which Surgery is the first listed.
NCT02017704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02017704 about?
NCT02017704 is a clinical study titled "Chemoradiation or Brachytherapy for Rectal Cancer". This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).
What is the current status of trial NCT02017704?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2014-06-12. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT02017704?
The interventions under investigation include: Surgery (PROCEDURE), IMRT (intensity modulated radiation therapy) (RADIATION), FOLFOX6 (DRUG), Endo-HDR (if randomized to this arm) (RADIATION), capecitabine and IMRT (if randomized to this arm) (DRUG).
Who is sponsoring clinical trial NCT02017704?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02017704's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI